ICM
RARE icon

IronBridge Capital Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

IronBridge Capital Management’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		$3.12M Buy
46,050
+15,230
+49% +$1.16M 0.19% 150
2016
Q4 		$2.17M Buy
+30,820
New +$2.19M 0.1% 144

Other funds holding RARE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
CGT
Capital Guardian Trust Los Angeles, California $7.42B AUM 13.6% 1-Year Est. Return

IronBridge Capital Management's RARE Position: Q1 2017 in Review

IronBridge Capital Management increased its Ultragenyx Pharmaceutical (RARE) stake by 49% in Q1 2017, buying an estimated $1.16M and bringing the position to 46,050 shares worth $3.12M. The position accounts for 0.19% of the portfolio, ranked #150.

IronBridge Capital Management first reported a position in RARE in Q4 2016 and has held it in 2 quarters since. 165 funds tracked by Wall St. Rank hold RARE as of Q1 2017.

  • IronBridge Capital Management held 46,050 shares of Ultragenyx Pharmaceutical worth $3.12M as of Q1 2017.
  • IronBridge Capital Management bought 15,230 Ultragenyx Pharmaceutical shares in Q1 2017, an estimated $1.16M.
  • Ultragenyx Pharmaceutical made up 0.19% of IronBridge Capital Management's portfolio in Q1 2017, its #150 holding.
  • IronBridge Capital Management first reported a position in Ultragenyx Pharmaceutical in Q4 2016 and has held it in 2 quarters since.
  • 165 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2017.

Based on IronBridge Capital Management's 13F filing for Q1 2017, filed 10 May 2017.